Emerald Advisers LLC Boosts Stock Position in TransMedics Group, Inc. (NASDAQ:TMDX)

Emerald Advisers LLC increased its stake in shares of TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 146.3% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 371,711 shares of the company's stock after acquiring an additional 220,804 shares during the quarter. Emerald Advisers LLC owned approximately 1.11% of TransMedics Group worth $23,176,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also bought and sold shares of the stock. Quarry LP grew its holdings in shares of TransMedics Group by 557.1% in the third quarter. Quarry LP now owns 368 shares of the company's stock worth $58,000 after purchasing an additional 312 shares during the last quarter. National Bank of Canada FI boosted its position in TransMedics Group by 174.7% during the 3rd quarter. National Bank of Canada FI now owns 412 shares of the company's stock valued at $65,000 after buying an additional 262 shares during the period. Hager Investment Management Services LLC bought a new stake in TransMedics Group in the 4th quarter worth $33,000. Sachetta LLC purchased a new position in shares of TransMedics Group in the fourth quarter valued at about $40,000. Finally, AlphaQuest LLC purchased a new position in shares of TransMedics Group in the fourth quarter valued at about $52,000. 99.67% of the stock is owned by hedge funds and other institutional investors.

TransMedics Group Stock Up 0.2 %

TransMedics Group stock traded up $0.12 on Thursday, hitting $70.44. 547,037 shares of the stock traded hands, compared to its average volume of 1,305,158. TransMedics Group, Inc. has a 1 year low of $55.00 and a 1 year high of $177.37. The firm has a market cap of $2.37 billion, a P/E ratio of 74.94 and a beta of 2.12. The company has a current ratio of 8.20, a quick ratio of 7.33 and a debt-to-equity ratio of 2.42. The business's fifty day simple moving average is $68.88 and its 200 day simple moving average is $88.90.

Remove Ads

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the company. Piper Sandler cut their target price on TransMedics Group from $110.00 to $90.00 and set an "overweight" rating on the stock in a research note on Wednesday, December 11th. JPMorgan Chase & Co. reiterated a "neutral" rating and issued a $75.00 price objective (down from $116.00) on shares of TransMedics Group in a research report on Tuesday, December 17th. Oppenheimer reissued an "outperform" rating and set a $125.00 target price on shares of TransMedics Group in a research note on Tuesday, December 3rd. Canaccord Genuity Group reaffirmed a "buy" rating and issued a $104.00 price target on shares of TransMedics Group in a research note on Tuesday, March 11th. Finally, Robert W. Baird reduced their price objective on shares of TransMedics Group from $150.00 to $120.00 and set an "outperform" rating on the stock in a research report on Wednesday, December 11th. Three analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $122.70.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.